Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
The effect of a dry salt inhaler in adults with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 106s Year: 2006
Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler Source: Virtual Congress 2021 – Environment and respiratory health Year: 2021
Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Inhaler choice in primary practice Source: Eur Respir Rev 2005; 14: 117-122 Year: 2005
Description of the UK’s asthma and COPD inhaler use Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018
Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009